RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up
Revvity (RVTY) reported Q2 2026 adjusted EPS of $1.41, up 19.5% and above the $1.23 Zacks estimate. Revenue rose 1.3% to $729.7 million, beating $704.5 million. Pro forma revenues were $711.1 million. Diagnostics grew; Life Sciences declined. Revvity raised 2026 pro forma revenue to $2.83-$2.86B and EPS to $5.30-$5.40 and agreed to divest China Immunodiagnostics.
How this was made
The 30-second read
Why it matters
Traders should focus on the combination of (1) Diagnostics-led growth and margin expansion, (2) Life Sciences organic decline driven by software weakness and timing, (3) tariff-related refunds boosting adjusted earnings, and (4) the raised 2026 pro forma outlook excluding the China IDX business.
Market read
A guidance raise with Diagnostics strength is the primary bullish input, but the disclosed organic Life Sciences weakness and tariff-refund contribution explain why shares fell pre-market.
What to watch
The China Immunodiagnostics divestiture is expected to close by end of 2027, so execution, regulatory, and cash-flow transition risk could weigh on valuation even after the near-term earnings beat.
Background
This is Revvity’s Q2 2026 earnings release with pro forma reporting excluding the China Immunodiagnostics business that the company agreed to divest.
Ticker impact
Revvity beat Q2 adjusted EPS ($1.41 vs $1.23) and raised 2026 pro forma revenue ($2.83-$2.86B) and EPS ($5.30-$5.40) guidance.
Bias modestly positive on guidance quality, but expect volatility given pre-market drop despite raised outlook and the disclosed reliance on tariff-related refunds plus Life Sciences organic decline.
The article provides multiple decision-grade datapoints: EPS and revenue beats, pro forma margin expansion, explicit guidance raise, and a specific divestiture agreement for China Immunodiagnostics with a long closing timeline.
Market effects
Diagnostics-focused outperformance and margin expansion reinforce a read-through that investors may reward diagnostics demand and efficiency gains within medical diagnostics.
Europe strength (double-digit gains) versus Americas decline (low-single digits) may shift regional positioning for diagnostics exposure.
China Immunodiagnostics divestiture agreement highlights ongoing portfolio reshaping in cross-border diagnostics, potentially affecting peers with China exposure.
Counterpoint
The raised guidance may be less durable if tariff-related refunds and one-off timing effects (software contract renewals) are masking underlying demand softness, especially in Life Sciences.
Key entities
- public_companyRevvity, Inc.
Reported Q2 2026 adjusted EPS and revenue beats, expanded margins, raised 2026 pro forma guidance, and agreed to divest China Immunodiagnostics.
- business_unitChina Immunodiagnostics business (China IDX)
Immunodiagnostics business in China that Revvity agreed to divest; expected close by end of 2027 and excluded from pro forma results.
